Question 1

What is Erasca's P/E ratio?

Accepted Answer

Erasca (ERAS) P/E ratio is currently not available. When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Erasca?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Erasca specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Why does Erasca's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 6

Why is Erasca's P/E ratio not available?

Accepted Answer

When trailing twelve-month earnings are negative (a net loss), the P/E ratio is mathematically meaningless and is reported as not available (N/A). In that case investors typically use P/S, EV/Sales, or forward P/E instead.


2025	$1.05B	-$125M	—	—	Dec 31, 2025
2024	$710M	-$162M	—	—	Dec 31, 2024
2023	$321M	-$125M	—	—	Dec 31, 2023
2022	$550M	-$243M	—	—	Dec 31, 2022
2021	$1.85B	-$123M	—	—	Dec 31, 2021
2020	$2.07B	-$102M	—	—	Dec 31, 2020


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Quest Diagnostics (DGX)	22.0×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
HCA Healthcare (HCA)	12.7×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Erasca (ERAS)

P/E Ratio daily chart for Erasca (ERAS)

Historical P/E Ratio for Erasca (ERAS) from 2020 to 2025

About P/E Ratio at Erasca (ERAS)

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Erasca (ERAS) Key Financials